XML 54 R45.htm IDEA: XBRL DOCUMENT v3.25.3
Business, Liquidity and Basis of Presentation (Narrative) (Details) - USD ($)
$ in Thousands
1 Months Ended 9 Months Ended
Nov. 07, 2025
Sep. 30, 2025
Oct. 08, 2025
Mar. 31, 2025
Dec. 31, 2024
Nov. 30, 2024
Sep. 30, 2024
Dec. 31, 2023
Product Information [Line Items]                
Cash, cash equivalents and short term investment   $ 3,500            
Cash and cash equivalents   3,458     $ 40,437   $ 44,784 $ 76,110
Accumulated deficit   2,172,187     $ 2,182,880      
Subordinated Notes [Member]                
Product Information [Line Items]                
Debt instrument, face amount   $ 10,500            
Debt instrument, maturity date   2026-06            
Promissory Note [Member]                
Product Information [Line Items]                
Debt instrument, face amount       $ 2,750   $ 22,000    
Subsequent Event [Member]                
Product Information [Line Items]                
Proceeds from sale of common stock $ 4,500              
Zydus Promissory Note Agreement [Member] | Subsequent Event [Member] | Promissory Note [Member]                
Product Information [Line Items]                
Debt instrument, face amount     $ 10,000          
MiNK Therapeutics, Inc.                
Product Information [Line Items]                
Reduction of ownership percentage   50.00%            
Recognized a gain on deconsolidation   $ 100,900            
Zydus Lifesciences Ltd | Subsequent Event [Member]                
Product Information [Line Items]                
Anticipative upfornt payment $ 91,000